Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States

作者：Rita Nanda, Clinton Yam, Laura M. Spring, Manali Ajay Bhave, I. Ntalla, T. Valdez, Brian Stwalley, Chang Yin Liang, Wenhui Wu, N. Sjekloca, Natalia Sadetsky, Catherine Lai, K. Kalinsky · 发表于：ESMO Open · 年份：2025 · DOI：10.1016/j.esmoop.2025.105308 · 被引用次数：7 · 研究领域：HER2/EGFR in Cancer Research、Advanced Breast Cancer Therapies、Cancer Treatment and Pharmacology

BACKGROUND: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, demonstrated efficacy and manageable safety in second-line or later (2L+) metastatic triple-negative breast cancer (mTNBC) in clinical trials. We describe the real-world effectiveness of SG as 2L+ mTNBC treatment and the proportion of patients with neutropenia and its management. PATIENTS AND METHODS: This study used a nationwide electronic health record-derived de-identified database. Patients with mTNBC receiving SG in 2L+ from April 2020 through June 2023 were included. Real-world overall survival (rwOS) and time to next treatment or death (TTNTD) were assessed using the Kaplan-Meier method. SG use patterns, rates of neutropenia, and granulocyte colony-stimulating factor (G-CSF) use were described. RESULTS: For 381 patients included in the analysis, the median [interquartile range (IQR)] age was 61 years (52-69 years); 17% (n = 66) had ECOG PS ≥2; 18% (n = 70) were black; 78% (n = 298) were treated in community settings. Patients received a median (IQR) of 2 (1-3) prior treatment lines for metastatic disease. Median (IQR) SG treatment duration was 4.0 months (1.9-7.6 months) (maximum 32.7 months). At a median (IQR) follow-up of 8.7 months (4.5-14.6 months), the median rwOS and TTNTD were 11.3 months [95% confidence (CI) 10.0-12.9 months] and 5.6 months (95% CI 5.0-6.4 months), respectively. Grade 2 and 3/4 neutropenia during SG treatment occurred in 25% (n = 94) and 27% (n = 101) of patients...